OncLive TV

Sylvia Adams, MD, discusses the utility of combining anti–CTLA-4 and anti–PD-1 agents in breast cancer.

Thomas Hope, MD, discusses the clinical impact of using 68Ga-PSMA-11 PET to detect pelvic nodal metastasis in men with intermediate- or high-risk prostate cancer.

Richard D. Kim, MD, discusses the efficacy of and next steps for a phase 1/1b study with regorafenib and nivolumab in patients with mismatch repair proficient advanced refractory colorectal cancer.

Ursula A. Matulonis, MD, discusses the current treatment landscape in ovarian cancer.

Harry H. Yoon, MD, discusses the updated results of the phase 3 KEYNOTE-061 trial in advanced gastric/gastroesophageal junction (GEJ) cancer.

Anant Ramaswamy, MD, discusses a phase 2 multicenter clinical trial evaluating the efficacy of capecitabine plus irinotecan versus irinotecan monotherapy in advanced gallbladder cancer.

Heinz-Josef Lenz, MD, FACP, discusses updated efficacy data from the phase 2 CheckMate-142 trial with nivolumab plus low-dose ipilimumab in metastatic colorectal cancer.

Daniel Catenacci, MD, discusses the challenges of developing novel therapies in gastroesophageal adenocarcinoma.

Marwan Fakih, MD, discusses the safety profile of AMG 510 in KRAS G12C-mutated colorectal cancer.

Solange Peters, MD,​ PhD, discusses ongoing research with ​fam-trastuzumab deruxtecan​-nxki (Enhertu; ​DS-8201) in patients with HER2-mutated non–small cell lung cancer.

Muhammad Bilal Abid, MD, MRCP, discusses the current coronavirus disease 2019 pandemic and its clinical impact on patients with cancer.

C. Ola Landgren, MD, PhD, discusses the efficacy of idecabtagene vicleucel in the treatment of patients with relapsed/refractory myeloma.

Othman Al-Sawaf, MD, discusses benefits of a fixed duration treatment versus continuous treatment in chronic lymphocytic leukemia.

Srdan Verstovsek, MD, PhD, discusses the limitations of the current treatment landscape of myelofibrosis.

Bradley J. Monk, MD, FACS, FACOG, discusses the utility of tisotumab vedotin in recurrent cervical cancer.

​Neal D. Shore, MD, FACS, discusses the safety profiles of relugolix and leuprolide in advanced prostate cancer.

Gary K. Schwartz, MD, discusses results of the Alliance A091401 trial (NCT02500797) in patients with metastatic sarcoma.

Bruno Sangro, MD, PhD, discusses the updated findings from the phase 3 CheckMate-459 trial, which evaluated the use of nivolumab and sorafenib in the treatment of patients with advanced hepatocellular carcinoma.

Jia Ruan, MD, PhD, discusses ​the utility of molecular profiling in mantle cell lymphoma.

Gaël Roué, PhD, discusses the synergistic activity with TG-1701, ublituximab, and umbralisib in ibrutinib-resistant mantle cell lymphoma models.

Huma Q. Rana, MD, MPH, discusses the prevalence of pathogenic variants in patients with prostate cancer enrolled on the ProGen study.

Caitlin Costello, MD, discusses the role of daratumumab in multiple myeloma.

Nikhil C. Munshi, MD, discusses the role of CAR T-cell therapy in relapsed/refractory multiple myeloma.

Shaji K. Kumar, MD, discusses stem cell mobilization multiple myeloma.

Katja Weisel, MD, discusses the safety profile of isatuximab-irfc in combination with carfilzomib, lenalidomide, and dexamethasone in high-risk patients with newly diagnosed multiple myeloma.

C. Ola Landgren, MD, PhD, discusses investigational cellular therapies in multiple myeloma.

Luciano J. Costa, MD, PhD, sheds light on CC-93269, a BCMA 2+1 T-cell engager, under examination in a phase 1 dose-finding study in relapsed/refractory multiple myeloma.

Caron Jacobson, MD, discusses the next steps with axicabtagene ciloleucel in relapsed/refractory indolent non-Hodgkin lymphoma.

Manfred Welslau, MD, discusses the rationale for investigating the Sandoz rituximab biosimilar, Rixathon, in combination with cyclophosphamide, doxorubicin, vincristine, and prednisone in diffuse large B-cell lymphoma.

Sattva Neelapu, MD, discusses the safety profile of ALLO-501 in combination with ALLO-647 in patients with relapsed/refractory large B-cell lymphoma or follicular lymphoma.